The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Response Genetics, Inc. on October 1, 2015. The debtor has been authorized to sell its substantially all its assets to Cancer Genetics, Inc., the stalking horse bidder for a purchase price of $7 million in cash, 788,584 shares of common stock of purchaser amounting to $7 million and assumption of assumed liabilities. The debtor did not receive any other competing bids for the purchase of its assets and therefore Cancer Genetics, Inc. emerged as the winning bidder.